



JUMP+ Plan



INTER PHARMA PUBLIC COMPANY LIMITED

(IP)

Year 2026 - 2028

This report was approved by the board of directors on 02/03/2026
and disseminated on 26/03/2026

Disclaimer

This document has been prepared by INTER PHARMA PUBLIC COMPANY LIMITED ("IP") based on information, assumptions, and projections of the Company as of the document preparation date. All plans, projects, proposals, opinions, forecasts, projections, or statements contained herein are provided solely for disclosure to interested parties.

The Company reserves the right to amend, modify, or update any project plans, including targets of the plans or projects described in this document at its sole discretion. The Company makes no representation or warranty regarding the accuracy, completeness, or validity of information contained herein, nor does it guarantee that the plans or projects outlined herein will successfully deliver outcomes according to the established targets or estimated timelines. All proposals, opinions, forecasts, projections, and forward-looking statements specified herein reflect the Company's views as of the document preparation date which are subject to risks and uncertainties and may change in the future according to changing economic conditions, competition, business-related factors, or any other factors. The Company assumes no obligation to update or revise such information or statements, except where the Company's Board of Directors approves any revisions to plans, targets, or other information that require the Company to disclose such changes through the system provided by The Stock Exchange of Thailand ("SET").

This document is intended only for disclosure to investors and related parties in general without the intent to solicit, recommend, induce, or offer opinions on investments in securities issued by the Company, nor shall it be construed as investment advice, an offer to buy or sell, or a solicitation for offers to buy or sell securities, or an inducement to engage in any transactions related to securities issued by the Company, particularly in any countries or special administrative regions where such acts may violate their applicable laws. No part of this document should be relied upon as a determining factor in making any decisions concerning the execution of contracts, agreements, or investments whatsoever. The Company and its directors, executives, and employees shall not be liable for any losses or damages, whether direct, indirect, compensatory, or consequential (including but not limited to loss of profits), arising from the use of or reliance on information contained herein, or from any variance between actual outcomes and the Company's forecasts or projections.

Investors are advised to exercise careful judgement and discretion in making investment decisions and to regularly review the Company's public disclosures such as information releases on material events, financial statements, Form 56-1 One Report, to support their prudent investment decisions with appropriate due diligence.

The role of The Stock Exchange of Thailand ("SET") is solely to initiate and facilitate the JUMP+ program which is intended to enable the growth and enhance the attractiveness of participating listed companies. SET does not participate or engage in the identification of the targets, forecasts, projections, and expected outcomes contained herein, nor does SET endorse the validity, accuracy, feasibility, and reasonableness thereof. The decision to rely on such information solely depends on the judgment and at the discretion of investors and related parties. SET and its directors, executives, and employees shall not be liable for any losses or damages, whether direct, indirect, compensatory, or consequential (including but not limited to loss of profits), arising from the use of or reliance on information contained herein, or from any variance between actual outcomes and the Company's forecasts or projections.

Table of Contents

	Page
Executive Summary	1
Section 1 Business Plan	2
Target in 2028	3
Strategic Plan : Elevating the innovation portfolio and manufacturing capabilities for long-term growth	3
Section 2 Governance Plan	6
Enhancing anti-corruption and fraud prevention efforts	7
Enhancing whistleblowing mechanisms	9
Enhancing the prevention of insider information	10
Section 3 Climate Action Plan	13
Greenhouse gas inventory (GHG) plan	14

SET
Consumer Products / Personal Products & Pharmaceuticals

CG Report :

SET ESG Ratings: -

Anti-Corruption Certification (CAC): -

Business Type

Research & development and distribution of healthcare products and aesthetic innovation products for human including health products for pets and livestock animals

Financial Statement				
Year	2025	2024	2023	2022
Income Statement (MB)				
Revenues	2,214.06	1,911.95	1,798.78	1,534.45
Expenses	2,022.09	1,836.42	1,689.37	1,362.74
Net Profit	122.38	37.28	50.79	119.24
Balance Sheet (MB)				
Assets	3,238.81	3,020.56	2,952.37	3,025.82
Liabilities	939.83	866.40	834.65	952.25
Shareholders' Equity	2,059.04	1,936.76	1,913.19	1,926.56
Cash Flow (MB)				
Operating	307.88	177.84	121.42	143.09
Investing	-170.49	-310.01	-232.77	-588.13
Financing	-41.26	-95.45	-252.86	1,047.85
Financial Ratio				
EPS (Baht)	0.20	0.06	0.14	0.36
GP Margin (%)	41.04	37.42	37.02	40.60
NP Margin (%)	6.15	1.97	3.27	8.34
D/E Ratio (Times)	0.41	0.40	0.39	0.46
ROE (%)	6.13	1.94	2.65	8.87
ROA (%)	6.09	2.48	3.58	7.85

JUMP+ Plan

Business Plan

Target in 2028

Revenue **2,910** Million Baht

Strategic Plan	Growth	Profitability & Efficiency	Stability
1. Strategic Plan : Elevating the innovation portfolio and manufacturing capabilities for long-term growth			

Governance Plan

1. Enhancing anti-corruption and fraud prevention efforts
2. Enhancing whistleblowing mechanisms
3. Enhancing the prevention of insider information

Climate Action Plan

1. Greenhouse gas inventory (GHG) plan

Remark : *This document has been prepared by the listed company for the purpose of disseminating corporate information to investors solely for their investment decision-making. The listed company does not provide any investment advice or recommendations regarding its securities. Investors are advised to conduct further research and consult with qualified professionals before making any investment decisions. The listed company shall not be held liable for any damages or losses arising from the use of information contained in this document under any circumstances. The listed company reserves the right to amend the information presented herein without prior notice. Reproduction, modification, or dissemination of this document or any part thereof is prohibited unless prior permission has been obtained from the listed company. For additional information, investors may refer to the reports or disclosures made available through the Office of the Securities and Exchange Commission and/or the Stock Exchange of Thailand.*

Section 1
Business Plan

Section 1 Business Plan

Target in 2028

Topic	YE/2023	YE/2024	YE/2025	Target in 2028
Revenue (Million Baht)	1,781.23	1,897.32	2,193.48	2,910

Committed to being a leader in the research and presentation of health products utilizing biotechnology for disease prevention, longevity, and anti-aging.

Growth plan/Increase business value

Strategic Plan : Elevating the innovation portfolio and manufacturing capabilities for long-term growth

Aims to develop specialized pharmaceutical innovations alongside upgrading production capacity to create high-quality new products and increase factory’s capability to support OEM work and expansion in both domestic and international markets.

This plan will promote and develop the organization in the following dimensions

- Growth

Targets

- Corporate Financial Targets

Topic	Latest data		Targets		
	YE/2024	YE/2025	2026	2027	2028
Revenue Growth (%)	6.29	15.80	10	10	10
YoY Growth Rate					

Strategic Initiative

Strategic Initiative	Year	Expected Outcomes
Accelerate the development and launch of high-value products for core target segments, alongside investments in equipment, tools, and machinery, as well as warehouse expansion and infrastructure and utilities development, to support new product manufacturing and capacity expansion	2026	<ul style="list-style-type: none"> • Develop new products under company brands and for OEM customers. • Begin recognizing revenue from certain new products within the year.
	2027	<ul style="list-style-type: none"> • Strengthen the product portfolio in segments with high profit potential.
	2028	<ul style="list-style-type: none"> • Generate full-year revenue from products and innovation projects developed during 2026–2027.
Operational Excellence and Systematic Cost Management	2026	<ul style="list-style-type: none"> • Achieve a significant reduction in unit costs. • Improve production capacity utilization rates.
	2027	<ul style="list-style-type: none"> • Further reduce unit costs significantly through Economies of Scale.
	2028	<ul style="list-style-type: none"> • Establish a highly Competitive Cost Structure.

Strategic Initiative	Year	Expected Outcomes
Expand distribution channels domestically and internationally, focusing on channels with high growth potential.	2026	<ul style="list-style-type: none"> Expand the customer base within high-potential distribution channels. Increase the revenue proportion from fast-growing channels.
	2027	<ul style="list-style-type: none"> Drive accelerated growth in revenue from core channels. Increase sales volume per point of sale. Reduce costs per channel through highly efficient management.
	2028	<ul style="list-style-type: none"> Expand to international markets and establish strategic partnerships.
Portfolio Restructuring to Increase High-Margin Product Proportion.	2026	<ul style="list-style-type: none"> Increase sales volume within product portfolio groups that have high profit potential.
	2027	<ul style="list-style-type: none"> Increase sales volume within product portfolio groups that have high profit potential.
	2028	<ul style="list-style-type: none"> Establish and maintain strong profit competitiveness in the long term.

Risk Management

Risk 1 : Delays in Approval from Regulatory Agencies

• **Risk Characteristic**

The new product development (NPD) process is highly complex and comprises several key stages, particularly in obtaining product approvals from relevant regulatory agencies. It requires extensive scientific data and factory assessments in accordance with EU GMP standards, which may lead to delays in the time-to-market for new products.

• **Risk Impact**

Delays in launching new products affect revenue and plans to expand into hospital and export markets.

• **Risk Management Measures**

Plan NPD activities in advance with a well-structured timeline, closely monitor the status of document submissions, collaborate proactively with regulatory agencies and consultants, and ensure all required documentation is fully prepared while responding to inquiries promptly.

Risk 2 : Risks from Hospital Channels and Procurement Policies

• **Risk Characteristic**

Hospitals may delay listing new drugs or adjust procurement policies due to budget constraints or clinical considerations, which could result in new products entering the market later than expected.

• **Risk Impact**

Order volumes and revenue may fall below target, potentially resulting in slower-than-planned growth in specialized markets such as ophthalmology, allergy, or herpes treatments.

• **Risk Management Measures**

Present the products to hospitals in advance, strengthen clinical information to support the sales team, and create differentiation in terms of quality and pricing.

Risk 3 : Intense Competition in both existing and new markets**• Risk Characteristic**

A large number of domestic and imported players in the market leads to intense competition in both pricing and product quality.

• Risk Impact

Market share may decline, profits may decrease, and new products may take longer to build a user base and achieve return on investment.

• Risk Management Measures

Develop the brand and unique selling points of the products, strengthen marketing plans, adjust pricing strategies to remain competitive, and expand export markets such as Hong Kong and Myanmar to reduce reliance on a single market.

Section 2

Governance Plan

Section 2 Governance Plan

Accountability and Transparency Governance

Enhancing anti-corruption and fraud prevention efforts

This initiative aims to establish a strong governance framework to combat all forms of corruption through the formulation, review, monitoring, and evaluation of compliance with internal policies and practices at least once a year. The company is also committed to fostering a culture of integrity and honesty among employees while pursuing national (CAC) and international (ISO) certifications to reinforce its dedication to ethical business conduct. These efforts are designed to build confidence and trust among investors and stakeholders, ensuring sustainable growth and long-term organizational resilience.

Targets

Topic	Current Status	Targets		
		2026	2027	2028
The company has established an anti-corruption policy and practices.	Complete	-	-	-
<ul style="list-style-type: none"> An anti-corruption and anti-bribery policy has been developed to comprehensively cover the organization's business operations, formally approved by the Board of Directors, and supported by clear and practical implementation guidelines 	Complete	-	-	-
<ul style="list-style-type: none"> The company conducts regular monitoring and evaluation of compliance with its anti-corruption and anti-bribery policy and procedures. Audit results are reported by internal auditors to the Board of Directors at least annually. In the event of any violations, corrective actions and preventive measures are clearly defined to prevent recurrence 	Complete	-	-	-
<ul style="list-style-type: none"> The company conducts an annual review of its anti-corruption and anti-bribery policy and practices with the Board of Directors 	Complete	-	-	-
Achieve CAC certification from the Thai Institute of Directors (Thai IOD)	Not Started	Signatory	In the process of applying for certification.	Certified
Create an E-learning module and online assessments.	-	In the process.	Success	Success

Strategic Initiative

Strategic Initiative	Year	Expected Outcomes
1. Obtaining CAC Certification from the Thai Institute of Directors (Thai IOD)	2026	<ul style="list-style-type: none"> Announce the intention to join the CAC project (Collective Action against Corruption, a program for the Thai private sector to combat corruption). Hire an external consultant to evaluate the company's readiness based on the 71-point assessment form (CAC Checklist).

Strategic Initiative	Year	Expected Outcomes
	2027	<ul style="list-style-type: none"> • Arrange for an organizational corruption risk assessment, focusing on areas related to transactions and contact with government agencies. • Establish policies where none currently exist and propose them for appropriate approval authority, while also developing various processes to align with the 71-point assessment. • Develop internal processes to align with the 71 points set by Thai IOD. • Announce and communicate the policy to all levels of employees for thorough awareness. • Compile and prepare all complete supporting documents required for the certification submission and submit documents for the first CAC certification request.
	2028	<ul style="list-style-type: none"> • Submit documents for the second CAC certification request (in case additional document revisions are required). • Officially receive CAC Certification from Thai IOD.
2. Create an E-learning module and online assessments	2026	<ul style="list-style-type: none"> • Enhance the presentation materials regarding anti-corruption and anti-bribery within the employee training curriculum and finalize the online testing system.
	2027	<ul style="list-style-type: none"> • Officially conduct the training across the entire organization, covering all employees, with the target for trainees to achieve a minimum assessment score of 80%.
	2028	<ul style="list-style-type: none"> • Review and update the content based on real-life case studies. • Prepare a summary report of the results for the Audit Committee and the Board of Directors.

Risk Management

Risk 1 : Risk arising from insufficient knowledge and understanding in preparing documentation and carrying out the procedures required to obtain certifications such as CAC.

• Risk Characteristic

The complex process of documentation may cause delay, resource consumption (time, budget, personnel), or errors due to operational mistakes or repeated document revision.

If the company announces its intention to participate but fails to gain certification, it may affect the company's image and reputation.

• Risk Impact

- Delays relative to the established plan.
- Failure to achieve certification as expected, which may negatively impact the organization's corporate image and credibility.

• Risk Management Measures

- Hire external experts with experience in CAC certification preparation to analyze improvement areas, check documentation accuracy, and assist in monitoring implementation before certification submission.
- Prepare a plan and track the progress of the processes with the relevant working team on a monthly basis.

Risk 2 : Risk from employees lacking knowledge and understanding of anti-corruption and bribery

• **Risk Characteristic**

Employees or related personnel may not participate in the training or may not give it importance, resulting in a lack of comprehensive understanding of the anti-corruption and bribery procedures.

• **Risk Impact**

Lack of awareness, knowledge, and understanding of anti-corruption and bribery procedures.

• **Risk Management Measures**

- Improve and update anti-corruption and anti-bribery content within the training curriculum for all employees.
- Track assessment results and conduct repeat training for those who do not meet the criteria, with a requirement that participants achieve a passing score of no less than 80%.

Enhancing whistleblowing mechanisms

This plan aims to enhance the organization’s whistleblowing and complaint reporting system to ensure efficiency, transparency, and protection for whistleblowers from retaliation or negative consequences. The objective is to establish multiple and confidential reporting channels that employees and stakeholders can trust, enabling them to report misconduct, misuse of internal information, or unethical behavior safely.

Targets

Topic	Current Status	Targets		
		2026	2027	2028
The company has established a whistleblowing policy and procedures for reporting misconduct.	Complete	-	-	-
• The company has established a formal,written whistleblowing policy and procedures,which have been approved by the Board of Directors	Complete	-	-	-
• Appointment of an impartial recipient for whistleblowing reports.	Complete	-	-	-
• All complaints are thoroughly investigated,and outcomes are reported to the Board in a timely manner,with appropriate corrective and preventive actions in cases of confirmed misconduct to avoid recurrence.	Complete	-	-	-
• The whistleblowing policy and procedures reviewed by the Board of Directors at least annually.	Complete	-	-	-
Create an E-learning module and online assessments.	-	In Progress	Success	Success

Strategic Initiative

Strategic Initiative	Year	Expected Outcomes
Create an E-learning module and online assessments	2026	<ul style="list-style-type: none"> Complete the preparation of presentation materials on whistleblowing/misconduct reporting to be included in the employee training curriculum and finalize the online testing system.
	2027	<ul style="list-style-type: none"> Officially conduct the training across the entire organization, covering all employees, with the target for trainees to achieve a minimum assessment score of 80%.
	2028	<ul style="list-style-type: none"> Review and update the content based on real-life case studies. Prepare a summary report of the results for the Audit Committee and the Board of Directors.

Risk Management

Risk 1 : Risk from Employees Lacking Knowledge on Whistleblowing

• Risk Characteristic

Employees or related personnel may not participate in the training or may not give it importance, resulting in a lack of comprehensive understanding of the whistleblowing process and ethics.

• Risk Impact

A lack of knowledge and understanding of whistleblowing procedures may cause employees to be hesitant to report irregularities or to report inaccurately.

• Risk Management Measures

- Include whistleblowing content in the training curriculum for employees.
- Track assessment results and conduct repeat training for those who do not meet the criteria, requiring them to pass the threshold of not less than 80%.

Enhancing the prevention of insider information

This plan aims to strengthen corporate governance systems in controlling and preventing the misuse of inside information. It is designed to prevent the use of non-public information for personal or unlawful gain by directors, executives, employees, or other related parties who may have access to the company’s confidential information.

Targets

Topic	Current Status	Targets		
		2026	2027	2028
The company has established a policy and procedures to prevent the misuse of insider information.	In Progress	In Progress	Success	Success
• A Board-approved written policy on insider information prevention has been clearly defined and implemented	Complete	-	-	-

Topic	Current Status	Targets		
		2026	2027	2028
<ul style="list-style-type: none"> A structured process is implemented to regularly monitor and review compliance with the insider trading prevention policy,with audits conducted at least annually. 	Not Started	In Progress	Success	Success
<ul style="list-style-type: none"> The implementation of the insider information prevention policy is reviewed and reported to the Board of Directors at least annually. If any violations are detected,corrective actions and preventive measures are clearly outlined to prevent recurrence 	Not Started	In Progress	Success	Success
Create an E-learning module and online assessments.	-	In Progress	Success	Success

Strategic Initiative

Strategic Initiative	Year	Expected Outcomes
1. Establish a Policy Monitoring and Auditing Process at least Once a Year	2026	<ul style="list-style-type: none"> Establish a Compliance Unit to provide consultation, advice, and warnings regarding the prevention of using inside information. Establish a working team to fully track the reporting of securities holdings by directors and executives. Prepare securities holdings report forms for directors, executives, and employees. Establish guidelines and procedures for reporting securities holdings.
	2027	<ul style="list-style-type: none"> All directors and executives report their annual securities holdings. The responsible team monitors and audits policy implementation at least once a year. Summarize audit results and report to the Board of Directors, along with corrective guidelines.
	2028	<ul style="list-style-type: none"> All directors and executives report their annual securities holdings. The responsible team monitors and audits policy implementation at least once a year. Summarize audit results and report to the Board of Directors, along with corrective guidelines.
2. Review the policy and guidelines and present them to the Board of Directors once a year.	2026	<ul style="list-style-type: none"> Plan the guidelines for reviewing policies and procedures. Establish a working team responsible for reviewing policies and procedures. Review the policy and procedure for using inside information for the first time to align with the changing context and regulations, and submit it to the Board of Directors.
	2027	<ul style="list-style-type: none"> Review the policy and procedure for using inside information to align with the changing context and regulations, and submit it

Strategic Initiative	Year	Expected Outcomes
	2028	<p>to the Board of Directors.</p> <ul style="list-style-type: none"> Review the policy and procedure for using inside information to align with the changing context and regulations, and submit it to the Board of Directors.
3. Create an E-learning module and online assessments	2026	<ul style="list-style-type: none"> Develop and improve presentation materials, introductory E-Learning content, and finalize the online testing system on the topic of preventing the misuse of insider information within the employee training curriculum.
	2027	<ul style="list-style-type: none"> Officially conduct the training across the entire organization, covering all employees, with the target for trainees to achieve a minimum assessment score of 80%.
	2028	<ul style="list-style-type: none"> Review and update the content based on real-life case studies. Prepare a summary report of the results for the Audit Committee and the Board of Directors.

Risk Management

Risk 1 : Risk from Non-Continuous Monitoring and Policy Review

• **Risk Characteristic**

Failure to consistently monitor and review compliance with the Insider Information Policy may lead to incomplete or irregular implementation, resulting in weak control systems and insufficient oversight.

• **Risk Impact**

Ineffective control over insider information usage may lead to unauthorized use, lack of transparency, and damage to the organization’s credibility and governance integrity.

• **Risk Management Measures**

- Require annual monitoring and reporting to the Audit Committee at least once a year.
- Prepare summary reports and continuously review and update related procedures to ensure effective implementation

Risk 2 : Risk from Employees’ Lack of Awareness and Understanding of Insider Information Policy

• **Risk Characteristic**

Employees or related personnel may not participate in the training or may not give it importance, resulting in a lack of comprehensive regarding the use of inside information and professional ethics.

• **Risk Impact**

Personnel lacking an understanding of policies and prohibitions regarding the use of inside information may lead to violations of capital market regulations and cause significant damage to the organization's reputation.

• **Risk Management Measures**

- Create an E-learning module and online assessments for the employee training program.
- Track assessment results and conduct repeat training for those who do not meet the criteria, requiring them to pass the threshold of not less than 80%.

Section 3

Climate Action Plan

Section 3 Climate Action Plan

Greenhouse gas inventory (GHG) plan

The Company has established a “Greenhouse Gas Inventory Plan” to enhance the management of environmental data in a systematic and reliable manner. The plan covers the collection of greenhouse gas emission data from the Company’s key operational activities, together with a framework for data verification by an external verifier accredited by the Thailand Greenhouse Gas Management Organization (TGO), as well as transparent disclosure of such information to stakeholders. Through this initiative, the Company seeks to strengthen the credibility of its business operations, reduce environmental impacts associated with its activities, and prepare for potential climate-related regulatory requirements in the future. The scope of the plan also extends to its subsidiary, Modern Pharma Company Limited, to ensure consistent environmental management practices across the Group.

Targets

Topic	Targets		
	2026	2027	2028
GHG inventory report, GHG verification and disclosure (specific to Scope 1 and Scope 2 emissions)	In Progress	Success	Success
Fostering an environmentally responsible organizational culture	In Progress	In Progress	Success

Strategic Initiative

Strategic Initiative	Year	Expected Outcomes
1. Preparation of the Organization’s Greenhouse Gas Inventory	2026	• Appoint a working committee in writing to oversee greenhouse gas management
		• Engage external experts or agencies as consultants for the preparation of the organization’s greenhouse gas inventory
		• Prepare and verify the organization’s greenhouse gas inventory for the year 2025 to inform subsequent decarbonization measures
	2027	• Disclose the 2025 greenhouse gas inventory data to stakeholders through at least one public communication channel
		• Prepare and verify the organization’s greenhouse gas inventory for the year 2026
		• Disclose the 2026 greenhouse gas inventory data to stakeholders through at least one public communication channel
2028	• Engage external experts or agencies as consultants for the preparation of the organization’s greenhouse gas inventory	
	• Prepare and verify the organization’s greenhouse gas inventory for the year 2027	
		• Disclose the 2027 greenhouse gas inventory data to stakeholders through at least one public communication channel

Strategic Initiative	Year	Expected Outcomes
2. Fostering an environmentally responsible organizational culture	2026	<ul style="list-style-type: none"> • Engage external experts or agencies as consultants for the preparation of the organization’s greenhouse gas inventory • Review the environmental policy at least once, with the review formally documented • Prepare communication materials such as posters, infographics, or announcement boards related to resource conservation, energy efficiency, water usage, or waste management, and disseminate them to employees within the organization at various locations, covering at least 2 points within the workplace • Develop a questionnaire to assess the effectiveness of the communication materials, with at least 20% of total employees participating in the survey • Publish a summary of the activities through at least one public communication channel
	2027	<ul style="list-style-type: none"> • Review the environmental policy at least once, with the review formally documented • Organize training programs for employees on environmental conservation, climate change, and other related topics, covering at least 20% of total employees at least once • Organize training programs for employees on environmental conservation, climate change, and other related topics, covering at least 20% of total employees at least once
	2028	<ul style="list-style-type: none"> • Review the environmental policy at least once, with the review formally documented • Initiate or participate in at least one environmental project or activity • Publish a summary of the activities through at least 2 public communication channels

Risk Management

Risk 1 : Risk of Natural Disasters Affecting Production and Warehouse Operations

• Risk Characteristic

Climate change has increased the frequency and severity of extreme weather events, such as flash floods, unseasonal storms, droughts, and extreme heat. These events may affect the Company’s production facilities, warehouses, and pharmaceutical storage systems that require strict temperature control, as well as related logistics operations.

• Risk Impact

Such events may disrupt production and product distribution, cause damage to goods, increase property repair costs, and affect the Company’s ability to maintain continuous product delivery.

• Risk Management Measures

The Company has established a Business Continuity Plan (BCP) covering disaster scenarios, including the provision of backup storage locations and emergency power systems. In addition, the Company is strengthening its energy resilience through the continued installation of solar power generation systems to support the stability of temperature control systems and reduce risks associated with energy supply fluctuations.

Risk 2 : Risk from the Expansion of Greenhouse Gas Reporting Boundaries

• **Risk Characteristic**

Currently, the Company prepares its greenhouse gas inventory covering only Scope 1 and Scope 2 emissions. However, evolving international standards and increasing stakeholder expectations may require the expansion of reporting boundaries to include Scope 3 emissions in the future, which relate to activities within the value chain, such as raw material procurement, transportation, and product distribution.

• **Risk Impact**

The expansion of reporting boundaries may increase the complexity of data collection and coordination with business partners. The Company may need to allocate additional resources to gather and verify data from external sources. In addition, the inclusion of Scope 3 emissions may result in a higher total volume of reported greenhouse gas emissions, which could affect the Company's emission reduction targets and environmental reputation.

• **Risk Management Measures**

The Company has established a structured framework for preparing its greenhouse gas inventory by appointing a working committee responsible for overseeing the development of data collection and management processes in alignment with relevant standards. In addition, the Company is assessing the feasibility of expanding emissions assessment to include Scope 3 categories, particularly significant activities within the value chain, in order to assess potential impacts and proactively prepare management measures in advance of future reporting requirements.
